Error loading player: No playable sources found
4275
Gut Microbiome — Ally or Foe for Immune Checkpoint Inhibitors
Date
May 20, 2024
SOCIETY: AGA This session will explore the complex dynamics between the gut microbiome and immune checkpoint inhibitors, addressing whether specific microbes/metabolites enhance therapeutic outcomes acting as allies or present challenges as potential foes, impacting treatment efficacy and associated side effects.
Moderators
Mayo Clinic
Stanford University
Related Products
Irritable Bowel Syndrome in Inflammatory Bowel Disease: Boundaries Along a Continuum
SOCIETY: AGA IBS-like symptoms in patients with IBD are common, yet presenting a diagnostic and clinical challenge for patients and their providers…
"Clinical Correlation Suggested": How to Handle Discrepancies Between Clinical and Pathologic Findings in Inflammatory GI Biopsies
SOCIETY: AGA This symposium focuses on frustrating scenarios where histopathologic examination of inflammatory gastrointestinal tract biopsies shows findings that do not match a patient's clinical scenario or provide a challenging differential diagnosis…
2024 AGA Guideline Highlights
SOCIETY: AGA AGA guidelines are among the most rigorously evidence-based and trusted guidelines in the field of GI and hepatology…
